| Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. | |
| | |
MedLine Citation:
|
PMID: 20808678 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study attempted to assess the incidence and outcome of anthracycline cardiotoxicity and the role of dexrazoxane as a cardioprotectant in childhood solid tumors. The dexrazoxane group included 47 patients and the control group of historical cohort included 42. Dexrazoxane was given in the 10:1 ratio to doxorubicin. Fractional shortening and systolic and diastolic left ventricular diameters were used to assess the cardiac function. The median follow-ups were 54 months in the dexrazoxane group and 86 months in the control group. The mean cumulative doses of doxorubicin were 280.8+/-83.4 mg/m(2) in the dexrazoxane group and 266.1+/-75.0 mg/m(2) in the control group. The dexrazoxane group experienced significantly fewer cardiac events (27.7% vs. 52.4%) and less severe congestive heart failure (6.4% vs. 14.3%) than the control group. Thirteen cardiotoxicities including one cardiac death and 2 congestive heart failures occurred in the dexrazoxane group, and 22 cardiotoxicities including 2 cardiac deaths and 4 congestive heart failures, in the control group. Five year cardiac event free survival rates were 69.2% in the dexrazoxane group and 45.8% in the control group (P=0.04). Dexrazoxane reduces the incidence and severity of early and late anthracycline cardiotoxicity in childhood solid tumors. |
| | |
Authors:
|
Hyoung Soo Choi; Eun Sil Park; Hyoung Jin Kang; Hee Young Shin; Chung Il Noh; Yong Soo Yun; Hyo Seop Ahn; Jung Yun Choi |
Related Documents
:
|
446138 - Oral therapy with phentolamine in chronic congestive heart failure. 6153888 - Disopyramide-induced ventricular tachycardia. 3741358 - Thin myofilament proteins in norm and heart failure. i. polymerizability of myocardial ... 17372478 - Cardiac amyloidosis: diagnostic features and clinical implications. 23536108 - Omega-3 polyunsaturated fatty acids delay the progression of endotoxic shock-induced my... 19028638 - Assessment of myocardial viability with cardiac magnetic resonance imaging. |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-08-12 |
Journal Detail:
|
Title: Journal of Korean medical science Volume: 25 ISSN: 1598-6357 ISO Abbreviation: J. Korean Med. Sci. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-02 Completed Date: 2010-12-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8703518 Medline TA: J Korean Med Sci Country: Korea (South) |
Other Details:
|
Languages: eng Pagination: 1336-42 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, Seoul National University Bundang Hospital, Sungnam, Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Antibiotics, Antineoplastic / adverse effects* Cardiomyopathies / chemically induced, prevention & control Cardiovascular Agents / therapeutic use* Child Child, Preschool Cohort Studies Disease-Free Survival Doxorubicin / adverse effects* Echocardiography Female Follow-Up Studies Heart Failure / chemically induced, prevention & control Humans Infant Male Neoplasms / drug therapy*, mortality Razoxane / therapeutic use* Ventricular Function, Left / physiology |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Cardiovascular Agents; 21416-87-5/Razoxane; 23214-92-8/Doxorubicin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Stress-induced alterations in mast cell numbers and proteinase-activated receptor-2 expression of th...
Next Document: Birth outcomes of Koreans by birthplace of infants and their mothers, the United States versus Korea...